3 models fit Teva Pharmaceutical Industries Limited American Depositary Shares and they disagree: 0 of 3 land within 15% of the average.
Two or more of our models back this value.
Premium(i)Silver70
Valued as a mature, profitable company: Discounted cash flow, P/E comparison, EV/EBITDA comparison, and Graham number.
ACCE opinionTeva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Fair value (3 models)
$28.07
ACCE price target
$39.00
Rating
Overvalued
Horizon
12 months
Fair value published on 19 Oct 2026, 19:04 CEST; previously $15.80 since 15 Oct 2026, 00:00 CEST.
ACCE price target published on 20 Sept 2026, 00:00 CEST.
Rating published on 19 Oct 2026, 19:04 CEST.
Price used: $39.41 at the close on 23 Oct 2026, 22:00 CEST.
Models: P/E comparison, EV/EBITDA comparison, and Graham number.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
40.4% above
-28.8% to fair value
ACCE score
59
out of 100
Analysts
92% buy
13 covering
P/E
65.7x
forward 12.8x
1-year return
+107.2%
Dividend yield
0.00%
Teva Pharmaceutical Industries Limited American Depositary Shares in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Teva is one of the largest generic drug makers in the world and also sells branded specialty drugs, including Austedo and Copaxone. Revenue fell 0.8%, and the operating margin is 4.0%, so the core generic business is under pressure. The trailing PE of 68.5 drops to 12.5 forward, which means the market expects a sharp earnings recovery. The internal score is 61/100.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
+Quarter-over-quarter institutional position changes
+Every insider and Congress trade, with how late it was disclosed
+Active 13D activist filings and top holders
Compare
Where it sits vs peers
News and Record
Press releases mentioning this company
Recent performance
1 week
-5.0%
1 month
+1.0%
3 months
+27.9%
6 months
+28.6%
YTD
+26.3%
1 year
+107.2%
SEC filings
Recommendation history, last 12 months
Date
Type
New
Previous
Price
19 Oct 2026, 19:04 CEST
Rating
Overvalued
first publication
$41.50
19 Oct 2026, 19:04 CEST
Fair value
$28.07
$15.80
$41.50
15 Oct 2026, 00:00 CEST
Fair value
$15.80
$28.69
$41.25
11 Oct 2026, 00:00 CEST
Fair value
$28.69
$16.09
$41.10
7 Oct 2026, 00:00 CEST
Fair value
$16.09
$16.35
$39.66
1 Oct 2026, 00:00 CEST
Fair value
$16.35
$23.81
$39.81
28 Sept 2026, 00:00 CEST
Fair value
$23.81
$16.68
$39.19
26 Sept 2026, 00:00 CEST
Fair value
$16.68
$16.24
$40.22
24 Sept 2026, 00:00 CEST
Fair value
$16.24
$16.54
$39.52
20 Sept 2026, 00:00 CEST
ACCE price target
$39.00
first publication
$38.98
Price
+108.0% · 1Y
Ask anything about TEVA
Answered from Teva Pharmaceutical Industries Limited American Depositary Shares fundamentals + recent valuations. Every number shows its source and date.
This stock Peer Peer median weaker → stronger
P/Ebetter than 33% of peers
low 13.5x65.7xhigh 67.8x
ROEbetter than 20% of peers
low 7%10%high 65%
Div yieldbetter than 0% of peers
low 0.0%0.0%high 2.6%
Peers
Prices Oct 23, 2026
Company
Price
Fair value
vs fair value
P/E
ROE
Quality
Score
TEVATeva Pharmaceutical Industries Limited American Depositary Shares
$39.41
$28
40% above
65.7x
9.7%
46
59
HLNHaleon plc American Depositary Shares (Each representing two Ordinary Shares)